Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics

被引:34
作者
Chua, Kyra [1 ]
Howden, Benjamin P. [1 ,2 ]
机构
[1] Austin Hlth, Dept Infect Dis, Heidelberg, Vic 3084, Australia
[2] Austin Hlth, Dept Microbiol, Heidelberg, Vic 3084, Australia
基金
英国医学研究理事会;
关键词
continuous infusion; Staphylococcus aureus; vancomycin; RESISTANT STAPHYLOCOCCUS-AUREUS; MINIMUM INHIBITORY CONCENTRATION; SKIN-STRUCTURE INFECTIONS; HIGH-DOSE VANCOMYCIN; REDUCED SUSCEPTIBILITY; INTERMITTENT INFUSION; INTENSIVE-CARE; DECREASED SUSCEPTIBILITY; BACTERICIDAL ACTIVITY; COMPLICATED SKIN;
D O I
10.1097/QCO.0b013e328331fbcd
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Purpose of review The role of vancomycin for treating serious methicillin-resistant Staphylococcus aureus infections and the optimal method of administration of anti-Gram-positive antibiotics. nave been recently questioned. This review summarizes the current literature concerning the use of vancomycin and the role of continuous infusion antimicrobials for treatment of Gram-positive infections. Recent findings Although vancomycin-resistant S. aureus due to acquisition of vanA from vancomycin-resistant enterococci remains rare (11 cases to date), heterogeneous vancomycin-intermediate S. aureus and vancomycin-intermediate S. aureus have now been reported from many countries around the world. Laboratory studies have demonstrated subtle, but potentially significant differences in vancomycin susceptibility depending on the methods used, meaning clinicians need to liaise closely with their local microbiology laboratories. Higher vancomycin minimum inhibitory concentrations within the accepted susceptible range and the presence of vancomycin-intermediate S. aureus are associated with vancomycin treatment failure. It is likely that heterogeneous vancomycin-intermediate S. aureus contributes to treatment failure in patients with serious, high bacterial load infections. Despite the potential limitations of vancomycin, no clinical trials have demonstrated superiority of alternative agents. Administration of antibiotics by continuous infusion is supported by in-vitro and animal studies for the classes of antibiotic that demonstrate time-dependent killing. However, few, limited clinical studies have been performed to date. Summary Vancomycin remains an important first-line antimicrobial for treatment of serious methicillin-resistant S. aureus infections; however, a detailed analysis of isolate susceptibility and appropriate dosing are important. Although continuous infusion of some anti-Gram-positive antimicrobials may provide theoretical benefits, clinical trials demonstrating superiority in outcomes are uncommon. Use of continuous infusion may, however, provide practical advantages in patients on home intravenous antibiotics.
引用
收藏
页码:525 / 534
页数:10
相关论文
共 68 条
[1]
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion [J].
Adembri, Chiara ;
Fallani, Stefania ;
Cassetta, Maria Iris ;
Arrigucci, Silvia ;
Ottaviano, Alessandra ;
Pecile, Patrizia ;
Mazzei, Teresita ;
De Gaudio, Raffaele ;
Novelli, Andrea .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (02) :122-129
[2]
Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini hospital in Tehran [J].
Aligholi, Marzieh ;
Emaneini, Mohammad ;
Jabalameli, Fereshteh ;
Shahsavan, Shadi ;
Dabiri, Hosein ;
Sedaght, Hossein .
MEDICAL PRINCIPLES AND PRACTICE, 2008, 17 (05) :432-434
[3]
Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage [J].
Alos, Juan-Ignacio ;
Garcia-Canas, Ana ;
Garcia-Hierro, Paloma ;
Rodriguez-Salvanes, Francisco .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (04) :773-775
[4]
Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus [J].
Cui, Longzhu ;
Neoh, Hui-min ;
Shoji, Mitsutaka ;
Hiramatsu, Keiichi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1231-1234
[5]
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients [J].
de Gatta Garcia, Maria del Mar Fernandez ;
Revilla, Natalia ;
Victoria Calvo, Maria ;
Dominguez-Gil, Alfonso ;
Sanchez Navarro, Amparo .
INTENSIVE CARE MEDICINE, 2007, 33 (02) :279-285
[6]
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection [J].
De Jongh, Raf ;
Hens, Ria ;
Basma, Violetta ;
Mouton, Johan W. ;
Tulkens, Paul M. ;
Carryn, Stephane .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :382-388
[7]
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug' [J].
Drusano, GL .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (04) :289-300
[8]
Vancomycin-Resistant Staphylococcus aureus, Michigan, USA, 2007 [J].
Finks, Jennie ;
Wells, Eden ;
Dyke, Teri Lee ;
Husain, Nasir ;
Plizga, Linda ;
Heddurshetti, Renuka ;
Wilkins, Melinda ;
Rudrik, James ;
Hageman, Jeffrey ;
Patel, Jean ;
Miller, Corinne .
EMERGING INFECTIOUS DISEASES, 2009, 15 (06) :943-945
[9]
Intermediate vancomycin susceptibility in a community-associated MRSA clone [J].
Graber, Christopher J. ;
Wong, Margaret K. ;
Carleton, Heather A. ;
Perdreau-Remington, Francoise ;
Haller, Barbara L. ;
Chambers, Henry F. .
EMERGING INFECTIOUS DISEASES, 2007, 13 (03) :491-493
[10]
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].
Hidayat, Levita K. ;
Hsu, Donald I. ;
Quist, Ryan ;
Shriner, Kimberly A. ;
Wong-Beringer, Annie .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144